Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

626
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
626
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.4K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.4K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Management of Adult Community-Acquired Pneumonia and Prevention - Update 2021 - Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIIN), the German Viological Society (DGV), the Competence Network CAPNETZ, the German College of General Practitioneers and Family Physicians (DEGAM), the German Society for Geriatric Medicine (DGG), the German Palliative Society (DGP), the Austrian Society of Pneumology Society (ÖGP), the Austrian Society for Infectious and Tropical Diseases (ÖGIT), the Swiss Respiratory Society (SGP) and the Swiss Society for Infectious Diseases Society (SSI)].

Pneumologie (Stuttgart, Germany)·2021
Same author

[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)].

Pneumologie (Stuttgart, Germany)·2020
Same author

[Evidence-based treatment of cystic fibrosis].

Der Internist·2020
Same author

[Management of Primary Ciliary Dyskinesia].

Pneumologie (Stuttgart, Germany)·2020
Same author

[Eosinophilic Granulomatosis with Polyangiitis with Pulmonary and Cardiac Involvement].

Pneumologie (Stuttgart, Germany)·2020
Same author

[The interdisciplinary orthogeriatric ward round : Recommendations for the clinical routine].

Der Unfallchirurg·2020

Related Experiment Video

Updated: Apr 7, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.2K

[PROGNOSIS - The PROspective German NOn-CF BronchiectaSIS Patient Registry].

J Rademacher1, A de Roux2, F C Ringshausen1

  • 1Medizinische Hochschule Hannover, Klinik für Pneumologie.

Pneumologie (Stuttgart, Germany)
|July 15, 2015
PubMed
Summary

This study introduces the German bronchiectasis registry PROGNOSIS to gather data on non-cystic fibrosis bronchiectasis (Non-CF bronchiectasis) in Germany. The registry aims to improve understanding of this condition and inform treatment guidelines.

More Related Videos

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.9K

Related Experiment Videos

Last Updated: Apr 7, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.2K
Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.9K

Area of Science:

  • Pulmonology
  • Epidemiology
  • Clinical Research

Background:

  • Non-cystic fibrosis bronchiectasis (Non-CF bronchiectasis) is a complex lung disorder with unknown prevalence and incidence in Germany.
  • Limited data exists on Non-CF bronchiectasis, often misclassified as a rare or orphan disease.
  • Currently, no approved therapies are available for Non-CF bronchiectasis in Germany.

Purpose of the Study:

  • Establish the German bronchiectasis registry PROGNOSIS (The PROspective German NOn-CF bronchiectaSIS patient registry).
  • Collect national, representative, prospective, and longitudinal data on Non-CF bronchiectasis patients.
  • Address critical epidemiological questions and aid in developing diagnostic and management guidelines.

Main Methods:

  • The PROGNOSIS registry will recruit at least 750 patients within three years.
  • Data collection will occur across 25-35 German centers in a non-interventional manner.
  • A German-language guideline for Non-CF bronchiectasis will be developed in collaboration with the German Respiratory Society (DGP).

Main Results:

  • The PROGNOSIS registry is set to commence patient recruitment in July.
  • The study aims to provide crucial epidemiological insights into Non-CF bronchiectasis.
  • Development of a national guideline will standardize care for Non-CF bronchiectasis.

Conclusions:

  • The PROGNOSIS registry is a vital initiative to understand Non-CF bronchiectasis in Germany.
  • This registry will facilitate the development of evidence-based treatment strategies.
  • Improved data collection and guideline development are expected to enhance patient care for Non-CF bronchiectasis.